Eli Lilly and Company has received its fourth U.S. Food and Drug Administration (FDA) approval for Cyramza
(ramucirumab). Cyramza is now
also indicated in combination with FOLFIRI chemotherapy for the treatment of patients with Metastatic Colorectal Cancer (mCRC) with disease progression on or after
prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
"Cyramza
now has approvals in advanced or metastatic forms of three of the
world's most common and deadly cancers, gastric, Non-small cell lung,
and colorectal, with four FDA approvals received in just over a year,"
said Sue Mahony, Ph.D., senior vice president and president, Lilly
Oncology. "This progress is encouraging and supports our ongoing
development program for Cyramza. Achieving today's milestone is another
example of Lilly's commitment to people living with gastrointestinal
cancers."
This site is for information on the various Chemo treatments and Stem Cell Therapies since 1992. This journey became bitter sweet in 2014, with the passing of my beautiful and dear wife. Sherry, had fought Non - Hodgkins Lymphoma(NHL) since 1990, in and out of remissions time and time again. From T-Cell therapies(1990's) to Dual Cord Blood Transplant(2014), she was in Clinical Trials over the years. This site is for informational purpose only and is not to promote the use of certain therapies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment